Fludeoxyglucose (18F)

Fludeoxyglucose (18F), also known as FDG, is a radioactive drug used in medical imaging, particularly in PET/CT scans. This article explores its use in clinical trials for various types of cancer, including pancreatic, lung, breast, and head and neck cancers. We’ll discuss how this imaging agent is being utilized to improve diagnostic accuracy, treatment planning, and assessment of therapy effectiveness in cancer patients.

Table of Contents

What is Fludeoxyglucose (18F)?

Fludeoxyglucose (18F), also known as 18F-FDG, FDG, or fluorodeoxyglucose (18F), is a special type of drug used in medical imaging[1]. It’s not a treatment drug, but rather a diagnostic tool that helps doctors see what’s happening inside your body[2].

How It Works

Fludeoxyglucose (18F) is used in a type of imaging called PET/CT, which stands for Positron Emission Tomography/Computed Tomography[1]. This is a sophisticated scanning technique that combines two types of images to give doctors a detailed look at your body’s structures and functions.

When you receive Fludeoxyglucose (18F), it travels through your body and is absorbed by cells that are using a lot of energy, such as cancer cells. The drug is slightly radioactive, which allows the PET scanner to detect where it has accumulated in your body[2].

Medical Uses

Fludeoxyglucose (18F) is used to help diagnose and monitor several conditions:

  • Cancer: It’s particularly useful in detecting and monitoring certain types of cancer, including:
    • Non-small cell lung cancer
    • Breast cancer
    • Head and neck cancer
  • Inflammation: It can help identify areas of inflammation in the body[2].
  • Pancreatic Cancer: In some studies, it’s used to help plan treatment for pancreatic cancer[1].

Administration

Fludeoxyglucose (18F) is given as a single intravenous (IV) injection. The dose is calculated based on each patient’s needs and the specific purpose of the scan[1][2]. After the injection, you’ll need to wait for a short period before the scanning begins, to allow the drug to distribute throughout your body.

Safety and Monitoring

While Fludeoxyglucose (18F) is generally considered safe, doctors carefully monitor patients after administration. This monitoring typically includes:

  • Vital signs: Doctors will check your ECG (a test that measures your heart’s electrical activity), blood pressure, heart rate, and body temperature[2].
  • Blood tests: These may include serum chemistry, clotting status, and hematology (blood cell counts)[2].
  • Adverse event collection: Doctors will keep track of any side effects or unexpected reactions[2].

These checks are typically done at least twice within 8 days after the procedure[2].

Aspect Details
Primary Use of Fludeoxyglucose (18F) Diagnostic imaging in PET/CT scans for cancer detection and monitoring
Cancer Types Studied Pancreatic, Non-small cell lung, Breast, Head and neck
Role in Treatment Planning Used for precise targeting in stereotactic body radiotherapy (SBRT)
Comparison Studies Evaluated against other tracers like BAY86-9596 for diagnostic performance
Safety Monitoring Vital signs, blood tests, adverse event reporting
Outcome Measures Tumor detection rate, quantitative uptake analysis (SUVs), progression-free survival, overall survival

Ongoing Clinical Trials on Fludeoxyglucose (18F)

  • Study of Gallium (68Ga) edotreotide, Fluorocholine (18F) and Fludeoxyglucose (18F) PET imaging for detection and staging of liver cancer and gastro-entero-pancreatic tumors

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France
  • Study on Brain Changes in Alzheimer’s Disease Using Flutemetamol (18F) and Fludeoxyglucose (18F) in ALFA Project Participants

    Recruiting

    1 1 1 1
    Spain
  • Study on Managing Rheumatological Side Effects in Cancer Patients Using Fludeoxyglucose (18F) and Checkpoint Inhibitors

    Recruiting

    1 1 1
    Investigated diseases:
    The Netherlands
  • Study on [68Ga]Ga-FAPI-46 and Fludeoxyglucose (18F) PET/CT Imaging for Evaluating Treatment Response in Patients with Advanced Malignant Melanoma

    Recruiting

    1 1 1
    Investigated diseases:
    Denmark
  • Comparing 18F-FDG and 68Ga-FAPI-46 for PET Scans in Patients with Hormone-Positive Breast Cancer

    Recruiting

    1 1 1
    The Netherlands
  • Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

    Recruiting

    1 1 1
    Denmark
  • Study on the Use of Fludeoxyglucose (18F) in PET/CT Scans for Young Patients with Histiocytosis

    Recruiting

    1 1 1 1
    Investigated drugs:
    Poland
  • Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

    Recruiting

    1 1 1
    Denmark
  • Study on the Use of 68Ga-FAPI-46 and Fludeoxyglucose (18F) for Diagnosing Pleural Mesothelioma in Patients

    Recruiting

    1 1 1
    Investigated diseases:
    Denmark
  • Study on Mosunetuzumab and Lenalidomide for Patients with Untreated Follicular Lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Austria Belgium France Germany Portugal Spain

Glossary

  • PET/CT: Positron Emission Tomography/Computed Tomography, a combined imaging technique that provides detailed information about both the structure and function of cells and tissues in the body.
  • Stereotactic Body Radiotherapy (SBRT): A highly precise form of radiation therapy that delivers high doses of radiation to specific areas of the body, often used to treat small, well-defined tumors.
  • Fiducials: Small, marker objects placed in or near a tumor to help guide radiation therapy by providing a reference point for targeting.
  • Gemcitabine: A chemotherapy drug commonly used to treat various types of cancer, including pancreatic cancer.
  • Standardized Uptake Values (SUVs): A measurement used in PET imaging to quantify the uptake of a radioactive tracer in body tissues, helping to assess the activity of tumors or other abnormalities.
  • Progression-Free Survival: The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Freedom From Local Progression (FFLP): A measure of how long a patient remains free from cancer growth at the original tumor site after treatment.
  • Gastrointestinal Toxicity: Side effects that affect the digestive system, such as nausea, vomiting, or diarrhea, which can occur as a result of cancer treatments.

References

  1. https://clinicaltrials.gov/study/NCT01146054
  2. https://clinicaltrials.gov/study/NCT01089998